KD2501

KD2501 is a generic small molecule non-steroidal anti-inflammatory drug (NSAID) candidate being developed by Kyungdong Pharmaceutical. It functions as an inhibitor of cyclooxygenase (COX) enzymes, specifically Prostaglandin-endoperoxide synthase 1 (COX-1) and Prostaglandin-endoperoxide synthase 2 (COX-2). These enzymes are responsible for the synthesis of prostaglandins, which are key mediators of pain, fever, and inflammation. By blocking this pathway, KD2501 provides analgesic and anti-inflammatory effects. The drug is currently in Phase 1 clinical development, likely involving bioequivalence studies to support its approval as a generic alternative for the management of various pain and inflammatory conditions.